Liling Delila
Overview
Explore the profile of Liling Delila including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
86
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu G, Chen H, Chang C, Chen Y, Wu Y, Widhibrata A, et al.
Biomaterials
. 2025 Mar;
319:123205.
PMID: 40023929
Platelet-derived extracellular vesicles (PEVs) have drawn attention due to their multifunctionality, ease of procurement, and abundant supply from clinical-grade platelet concentrates. PEVs can be readily endocytosed due to their lipid...
2.
Delila L, Nebie O, Le N, Timmerman K, Lee D, Wu Y, et al.
J Biomed Sci
. 2024 Sep;
31(1):87.
PMID: 39237980
Background: The burgeoning field of regenerative medicine has significantly advanced with recent findings on biotherapies using human platelet lysates (HPLs), derived from clinical-grade platelet concentrates (PCs), for treating brain disorders....
3.
Le N, Han C, Delila L, Nebie O, Chien H, Wu Y, et al.
APL Bioeng
. 2024 May;
8(2):026111.
PMID: 38726021
Human platelet lysates (HPLs) from allogeneic platelet concentrates (PCs) are biomaterials, which are rich in various trophic factors, increasingly used in regenerative medicine and biotherapy. Understanding how preparation methods influence...
4.
Wu Y, Lee D, Lu Y, Delila L, Nebie O, Barro L, et al.
Platelets
. 2023 Aug;
34(1):2237134.
PMID: 37580876
Platelet extracellular vesicles (PEVs) are an emerging delivery vehi for anticancer drugs due to their ability to target and remain in the tumor microenvironment. However, there is still a lack...
5.
Delila L, Nebie O, Le N, Barro L, Chou M, Wu Y, et al.
Bioeng Transl Med
. 2023 Jan;
8(1):e10360.
PMID: 36684076
Brain administration of human platelet lysates (HPL) is a potential emerging biotherapy of neurodegenerative and traumatic diseases of the central nervous system. HPLs being prepared from pooled platelet concentrates, thereby...
6.
Widyaningrum R, Wu Y, Delila L, Lee D, Wang T, Burnouf T
Platelets
. 2022 Aug;
33(8):1237-1250.
PMID: 35949054
Corneal endothelial cells (CECs) slowly decrease in number with increasing age, which is a clinical issue as these cells have very limited regenerative ability. Therapeutic platelet biomaterials are increasingly used...
7.
Nyam-Erdene A, Nebie O, Delila L, Buee L, Devos D, Chou S, et al.
ACS Biomater Sci Eng
. 2021 Nov;
7(12):5823-5835.
PMID: 34846835
Human platelet lysates (HPLs) made from clinical-grade platelet concentrates are currently evaluated in the preclinical models of Parkinson's disease, Alzheimer's disease, traumatic brain injury, and others, as a new polyvalent...
8.
Widyaningrum R, Burnouf T, Nebie O, Delila L, Wang T
Biomed Pharmacother
. 2021 Aug;
142:112046.
PMID: 34426259
Human platelet lysate (HPL) is a complex mixture of potent bioactive molecules instrumental in tissue repair and regeneration. Due to their remarkable safety, cost-effective production, and availability at global level...
9.
Barro L, Delila L, Nebie O, Wu Y, Knutson F, Watanabe N, et al.
Cytotherapy
. 2021 Jul;
23(10):902-907.
PMID: 34238658
Background Aims: Platelet concentrates (PCs) are pooled to prepare human platelet lysate (HPL) supplements of growth media to expand primary human cells for transplantation; this increases the risk of contamination...
10.
Nebie O, Carvalho K, Barro L, Delila L, Faivre E, Renn T, et al.
Brain
. 2021 Jun;
144(10):3142-3158.
PMID: 34086871
Traumatic brain injury (TBI) leads to major brain anatomopathological damages underlined by neuroinflammation, oxidative stress and progressive neurodegeneration, ultimately leading to motor and cognitive deterioration. The multiple pathological events resulting...